Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
The effect of superoxide anion and hydrogen peroxide imbalance on prostate cancer: an integrative in vivo and in vitro analysis.
|
26468117 |
2015 |
Prostatic Neoplasms
|
0.370 |
Therapeutic
|
group |
CTD_human |
The effect of superoxide anion and hydrogen peroxide imbalance on prostate cancer: an integrative in vivo and in vitro analysis.
|
26468117 |
2015 |
Prostatic Neoplasms
|
0.370 |
Therapeutic
|
group |
CTD_human |
Association between gene polymorphism of manganese superoxide dismutase and prostate cancer risk.
|
23315858 |
2013 |
Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
Association between gene polymorphism of manganese superoxide dismutase and prostate cancer risk.
|
23315858 |
2013 |
Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
Heterocyclic aromatic amine [HCA] intake and prostate cancer risk: effect modification by genetic variants.
|
22564066 |
2012 |
Prostatic Neoplasms
|
0.370 |
Therapeutic
|
group |
CTD_human |
Heterocyclic aromatic amine [HCA] intake and prostate cancer risk: effect modification by genetic variants.
|
22564066 |
2012 |
Prostatic Neoplasms
|
0.370 |
Therapeutic
|
group |
CTD_human |
In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration.
|
19074884 |
2008 |
Prostatic Neoplasms
|
0.370 |
GeneticVariation
|
group |
LHGDN |
Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control group.
|
18571701 |
2008 |
Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration.
|
19074884 |
2008 |
Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.
|
18829485 |
2008 |
Prostatic Neoplasms
|
0.370 |
Therapeutic
|
group |
CTD_human |
Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.
|
18829485 |
2008 |
Prostatic Neoplasms
|
0.370 |
GeneticVariation
|
group |
LHGDN |
Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk.
|
18784358 |
2008 |
Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration.
|
19074884 |
2008 |
Prostatic Neoplasms
|
0.370 |
Therapeutic
|
group |
CTD_human |
Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study.
|
17646272 |
2007 |
Prostatic Neoplasms
|
0.370 |
GeneticVariation
|
group |
LHGDN |
Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study.
|
17646272 |
2007 |
Prostatic Neoplasms
|
0.370 |
Therapeutic
|
group |
CTD_human |
Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study.
|
17465268 |
2007 |
Prostatic Neoplasms
|
0.370 |
GeneticVariation
|
group |
LHGDN |
Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study.
|
17465268 |
2007 |
Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study.
|
17646272 |
2007 |
Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study.
|
17465268 |
2007 |
Prostatic Neoplasms
|
0.370 |
AlteredExpression
|
group |
LHGDN |
Overexpression of manganese superoxide dismutase promotes the survival of prostate cancer cells exposed to hyperthermia.
|
15512801 |
2004 |
Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
LHGDN |
Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.
|
12592389 |
2003 |
Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.
|
12592389 |
2003 |
Prostatic Neoplasms
|
0.370 |
Therapeutic
|
group |
CTD_human |
Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.
|
12592389 |
2003 |
Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.
|
12592389 |
2003 |